Immunotech Biopharm Ltd Obtains the Clinical Approval for the Denocabtagene Ciloleucel Injection from the National Medical Products Administration
effective in the treatment of patients with relapsed and refractory lymphoma. Despite this, CAR-T cells' therapeutic effect on a certain proportion of patients is still very poor partly because of mechanisms in lymphomas to evade attack by the immune system, as is the case of most other malignant solid tumours. The functional components of the Denocabtagene Ciloleucel Injection are T cells that are genetically modified to express an anti-CD19 chimeric antigen receptor and an antagonist of proteins in the downstream signaling of TGF-ß. CD19 is widely expressed on the surface of B cells during all phases of B cell development. Furthermore, the vast majority of tumour cells from diseases caused by the mutation of B cells and their precursor cells such as B cell lymphoma and acute B lymphocytic leukaemia also express CD19, making CD19 one of the targets for the treatment of these tumours. By linking the anti-CD19 single-chain antibody, protein transmembrane domain, and co-stimulatory molecular domain, the technology may avoid issues such as the failure of autoimmune cells to recognise human CD19 protein, the inhibition of tumour cells on immune cells and the insufficient second messenger signalling pathway. This may enable the modified T cells to directly recognise the CD19 molecule and kill the cells carrying the target, thereby achieving the purpose of treating the tumour. In addition, the synchronisation of transcription and translation of the antagonist of proteins in the downstream signaling of TGF-ß within the cells has the potential to inhibit the immunosuppressive effect caused by TGF-ß in the tumour microenvironment and prevent the weakening and depletion of CAR-T cells' immune killing ability, thereby further improving
the therapeutic effect.